Allergen Immunotherapy: History and Future Developments

Immunology and Allergy Clinics of North America

Volumn 36, Issue 1, 2016, Pages 1-12

  Passalacqua, Giovanni ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergen immunotherapy; Efficacy; History; Indications; Molecular diagnosis; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; FOOD ALLERGEN; POLLEN EXTRACT; VENOM;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGY; ANTIGEN SPECIFICITY; CLINICAL PROTOCOL; DESENSITIZATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INSECT ALLERGY; MEDICAL HISTORY; MEDICAL RESEARCH; MOLECULAR DIAGNOSIS; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; STANDARDIZATION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT RESPONSE; ANIMAL; HISTORY; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

ALLERGY AND IMMUNOLOGY; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84947902877     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.08.001     Document Type: Review

References (75)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, i:1572-1573.
2. Johansson S.G.O. The History of IgE: from discovery to 2010. Curr Allergy Asthma Rep 2011, 11:173-177.
3. Frankland A.W., Augustin R. Prophylaxis of summer hay fever and asthma: controlled trial comparing crude grass pollen extracts with isolated main protein component. Lancet 1954, 1:1055-1057.
4. Johnstone D.E., Dutton A. The value of hyposensitization therapy for bronchial asthma in children: a 14-year study. Pediatrics 1968, 42:793-802.
5. Hunt K.J., Valentine M.D., Sobotka A.K., et al. A controlled trial of immunotherapyin insect hypersensitivity. N Engl J Med 1978, 299:157-161.
6. Lockey R.F., Turkeltaub P.C., Olive E.S., et al. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990, 86:775-780.
7. Lockey R.F., Benedict L.M., Turkeltaub P.C., et al. Fatalities associated with immunotherapy and skin testing. J Allergy Clin Immunol 1987, 79:660-664.
8. Committee on the Safety of Medicines CSM update. Desensitizing vaccines. Br Med J 1986, 293:948.
9. Aaronson D.W., Gandhi T.K. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004, 113:1117-1121.
10. Windom H.H., Lockey R.F. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008, 8:571-576.
11. Canonica G.W., Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003, 111:437-448.
12. Scadding K., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986, 16:483-491.
13. Bousquet J., Lockey R., Malling H.J. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. J Allergy Clin Immunol 1998, 102(4 Pt 1):558-562.
14. Bousquet J., Van Cauwenberge P. Allergic rhinits and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Supp):S146-S150.
15. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
16. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991, 12:256-257.
17. James L.K., Shamji M.H., Walker S.M., et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127:509-516.
18. Rolland J.M., Gardner L.M., O'Hehir R.E. Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol 2010, 10(6):559-566.
19. Böhm L., Maxeiner J., Meyer-Martin H., et al. IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma. J Immunol 2015, 194(3):887-897.
20. Fujita H., Soyka M.B., Akdis M., et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012, 2(1):2.
21. Möller C., Dreborg S., Ferdousi H.A., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
22. Novembre E., Galli E., Landi F., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
23. Marogna M., Tomassetti D., Bernasconi A., et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008, 101:206-211.
24. Durham S.R., Yang W.H., Pedersen M.R., et al. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802.
25. Didier A., Malling H.J., Worm M., et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338.
26. Creticos P.S., Maloney J., Bernstein D.I., et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013, 131:1342-1349.
27. Nolte H., Hébert J., Berman G., et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 2013, 110:450-455.
28. Mosbech H., Deckelmann R., de Blay F., et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014, 134:568-575.
29. Bergmann K.C., Demoly P., Worm M., et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014, 133:1608-1614.
30. Frew A., Powell J.L., Corrigan C.J., et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319-325.
31. Canonica G.W., Bousquet J., Casale T., et al. Sub-lingual immunotherapy World Allergy Organization Position Paper 2009. Allergy 2009, 64(Supp 91):1-59.
32. Canonica G.W., Cox L., Pawankar R., et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014, 7(1):6.
33. Thompson C.A. Sublingual immunotherapy approved for grass pollen allergies. Am J Health Syst Pharm 2014, 71:770.
34. Passalacqua G., Albano M., Fregonese L., et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998, 351:629-632.
35. Lombardi C., Incorvaia C., Braga M., et al. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?. Allergy 2009, 64:849-854.
36. Pajno G.B., Caminiti L., Crisafulli G., et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011, 22:803-807.
37. Stelmach I., Kaluzińska-Parzyszek I., Jerzynska J., et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012, 67:312-320.
38. 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.
39. Cox L., Nelson H., Lockey R., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(1 Suppl):S1-S55.
40. Cox L., Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009, 103:451-459.
41. Nelson H.S. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009, 123:763-769.
42. Malling H.J., Montagut A., Melac M., et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009, 39:387-393.
43. Hankin C.S., Cox L. Allergy immunotherapy: what is the evidence for cost saving?. Curr Opin Allergy Clin Immunol 2014, 14:363-370.
44. Senna G., Ridolo E., Calderon M., et al. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9:544-548.
45. Senna G., Lombardi C., Canonica G.W., et al. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010, 126:668-669.
46. Savi E., Peveri S., Senna G., et al. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy 2013, 68:1193-1195.
47. Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy 2010, 40:1442-1460.
48. 2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 2013, 6(1):17.
49. Sastre J., Landivar M.E., Ruiz-García M., et al. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012, 67(5):709-711.
50. Passalacqua G., Melioli G., Bonifazi F., et al. The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy 2013, 68:1029-1033.
51. Melioli G., Passalacqua G., Canonica G.W. Novel in silico technology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management?. Expert Rev Clin Immunol 2014, 10:1559-1561.
52. Baena Cagnani C.E., Larenas D., Sisul C., et al. Allergy training and immunotherapy in Latin America: results of a regional overview. Ann Allergy Asthma Immunol 2013, 111(5):415-419.
53. Kaul S., May S., Lüttkopf D., et al. Regulatory environment for allergen-specific immunotherapy. Allergy 2011, 66:753-764.
54. Bonini S. Regulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach. World Allergy Organ J 2012, 5:120-123.
55. Albin S., Nowak-Wegrzyn A. Potential treatments for food allergy. Immunol Allergy Clin North Am 2015, 35:77-100.
56. Jones S.M., Burks A.W., Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol 2014, 133:318-323.
57. Nettis E., Delle Donne P., Di Leo E., et al. Latex immunotherapy: state of the art. Ann Allergy Asthma Immunol 2012, 109:160-165.
58. Gendelman S.R., Lang D.M. Sublingual immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Curr Allergy Asthma Rep 2015, 15:498-507.
59. Bae J.M., Choi Y.Y., Park C.O., et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013, 132:110-117.
60. Senti G., Prinz Vavricka B.M., Erdmann I., et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008, 105:17908-17912.
61. Witten M., Malling H.J., Blom L., et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?. J Allergy Clin Immunol 2013, 132:1248-1252.
62. Senti G., von Moos S., Tay F., et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015, 10.1111/all.12600.
63. Aryan Z., Holgate S.T., Radzioch D., et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014, 164:46-63.
64. Pfaar O., Cazan D., Klimek L., et al. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12:648-657.
65. Creticos P.S., Schroeder J.T., Hamilton R.G., et al. Immune Tolerance Network Group Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
66. Creticos P.S., Chen Y.H., Schroeder J.T. New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol Allergy Clin North Am 2004, 24:569-581.
67. Creticos P.S. Advances in synthetic peptide immuno-regulatory epitopes. World Allergy Organ J 2014, 7(1):30.
68. Pauli G., Larsen T.H., Rak S., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
69. Tripodi S., Frediani T., Lucarelli S., et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol 2012, 129:834-839.
70. Passalacqua G., Canonica G.W. Sublingual immunotherapy: focus on tablets. Ann Allergy Asthma Immunol 2015, 115(1):4-9.
71. Nakonechna A., Hills J., Moor J., et al. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy?. Ann Allergy Asthma Immunol 2015, 114:73-74.
72. Stelmach I., Sobocińska A., Majak P., et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012, 109:274-278.
73. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol 2011, 107:401-406.
74. Casale T.B., Canonica G.W., Bousquet J., et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009, 124:665-670.
75. Bousquet P.J., Calderon M.A., Demoly P., et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011, 127:49.